Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

Crohn's Disease Clinical Trial

Official title:

Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00509639
• Other study ID #: MET/01
• Status: Completed
• Phase: Phase 3
• First received: July 30, 2007
• Last updated: December 12, 2012
• Start date: May 2005
• Est. completion date: February 2008

Study information

• Verified date: December 2012
• Source: S.L.A. Pharma AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare changes in Perianal Crohn's Disease following use of locally applied 10% metronidazole ointment and a placebo.

Description:

Anorectal Crohn's disease is one of the most problematic and debilitating conditions encountered in colorectal practise. The condition is usually chronic, debilitating, and frequently refractory to current medications. Failure to respond to medical therapy may ultimately result in proctocolectomy and ileostomy, even in the absence of more proximal colonic disease. Isolated anorectal Crohn's disease is reported in 3 to 5% of Crohn's patients. In Crohn's patients as a whole, anorectal involvement is reported in up to one third to one half of patients, in addition to either colonic or enteric Crohn's disease. In spite of the previously reported painless nature of anorectal Crohn's disease, it is the author's experience that the condition can be inordinately painful due to deeply eroding fissures, oedematous skin tags, and painful induration of the perianal region.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: February 2008
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have Crohn's disease (diagnosed by radiology, endoscopy and pathology), with anorectal involvement.

• Have had perianal symptoms for longer than 3 months

• Have a PCDAI of 5 or above at baseline

• Subjects can be on concomitant medication. Acceptable regimes are:-

• Aminosalicylates at a dosage that has been stable for more than 4 weeks before screening;

• Oral corticosteroids <40mg per day that has been stable for more than 3 weeks;

• Methotrexate given for at least 3 months that has been stable for more than 4 weeks; Azathioprine or mercaptopurine given for at least 6 months at dosage that has been stable for more than 8 weeks;

• Antibiotics at a dosage that has been stable for 4 weeks (subjects may be on oral metronidazole but on a dose not more than 750mg per day),

• Cycolsporin for more than 3 months and on a stable dose for more than 4 weeks;

• Patients who have been treated with Infliximab must have received their initial dose 3 months before starting study medication and their most recent dose at least 8 weeks before starting study medication and not receive an infusion whilst in the double-blind treatment phase of the study for 4 weeks. During the second 4 week open stage of the study patients can commence again a maintenance regime with Infliximab treatment if deemed necessary

• Any patients not on concurrent medication must have been off medication for at least 4 weeks before screening.

• If patients have Setons these must have been in place for at least 4 weeks prior to screening.

• Subjects must be aged 18 years or over and of the legal age of consent.

• If female, the subject must not be lactating and must be (a) post- menopausal, (b) surgically sterilised, or (c) have a negative pregnancy test result prior to entry into the study and will use double- barrier methods of contraception (two separate methods of birthcontrol one of which may include oral contraception) for the duration of the study.

• Must have provided written informed consent to participate.

Exclusion Criteria:

• They have had surgery to the anus or rectum in the past 4 weeks;

• They have a perianal abscess requiring incision and drainage;

• They have a stoma of less than 6 months duration;

• Allergic to metronidazole;

• Are taking any prohibited medication.

• Deemed mentally incompetent.

• Considered by their physician unlikely to be able to comply with the protocol.

• Taken part in an experimental drug study in the preceding three months.

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Drug:
• 10% Metronidazole Ointment
Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks

Locations

Country	Name	City	State
United Kingdom	Monklands Hospital	Airdrie
United Kingdom	Birmingham Heartlands Hospital	Birmingham
United Kingdom	Bristol Royal Infirmary	Bristol
United Kingdom	University Hospital of Wales	Cardiff
United Kingdom	University Hospital of Warwick and Coventry	Coventry
United Kingdom	Derby City General Hospital	Derby	Derbyshire
United Kingdom	St Marks Hospital	Harrow
United Kingdom	Leicester General Hospital	Leicester	Leicestershire
United Kingdom	St Thomas Hospital	London
United Kingdom	Peterborough District Hospital	Peterborough
United States	Washington University School of Medicine	St Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
S.L.A. Pharma AG

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the effect of 10% metronidazole ointment, applied topically three times a day, in and around the anus, on the change in perianal Crohn's disease activity.	Perianal Crohn's Disease Activity Index	Four weeks
Secondary	To evaluate and compare the relief of perianal pain and discomfort associated with Crohn's disease, against placebo.	Perianal Crohn's Disease Activity Index plus Visual Analogue Scale for perianal pain	4 weeks
Secondary	To evaluate and compare Patient Global Impression of Improvement	Patient Global Impression of Improvement (numerical scale)	4 weeks
Secondary	To compare visual improvement (using photographic documentation assessed by a blinded independent observer)	Photographic record	4 weeks
Secondary	To compare Quality of Life assessments	Short Form 12 Questionnaire	4 weeks
Secondary	To evaluate and compare the number of analgesics required prior to treatment and to that required by the treatment and placebo group	Usage of analgesics during the treatment period	4 weeks
Secondary	To evaluate and compare fistula healing	Visual assessment of fistula healing	4 weeks